Furosemide vs Torsemide: Similar Outcomes Observed in Heart Failure Study
The phase 3 TRANSFORM-HF trial enrolled nearly 3000 hospitalized patients with heart failure.
The phase 3 TRANSFORM-HF trial enrolled nearly 3000 hospitalized patients with heart failure.
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
Mavacamten is an oral, selective allosteric inhibitor of cardiac myosin.
Etripamil is a self-administered nasal spray designed to be a rapid-response therapy for episodic cardiovascular conditions.
Bivalent COVID-19 booster vaccines for children; wearable device to help treat fluid overload in adults with chronic heart failure; real-world data insights into molnupiravir efficacy; vaccine for the third trimester of pregnancy to prevent pertussis; and an FDA update on apomorphine infusion in Parkinson disease.
Furoscix is a pH-neutral formulation of furosemide designed for SC administration via a wearable, single-use, pre-programmed on-body infusor for outpatient self-administration.
Quality of YouTube videos for patients considering an implantable cardioverter defibrillator found to be highly variable, poor overall
Stay up-to-date on the latest drugs in development.
Rate of successful decongestion higher with addition of acetazolamide to loop diuretic in patients with acute decompensated heart failure